Association between the Number of Repeated Praziquantel Treatments and Kidney Parenchymal Change in Northeast Thailand.
Screening
Ultrasonography
kidney parenchymal change
praziquantel treatment
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Jul 2022
01 Jul 2022
Historique:
received:
13
02
2022
entrez:
28
7
2022
pubmed:
29
7
2022
medline:
2
8
2022
Statut:
epublish
Résumé
In Northeast Thailand, Praziquantel (PZQ) is used to treat infection with the Opisthorchis viverrnini (OV). OV has highly prevalence in this area due to the traditional consumption of uncooked cyprinid fish. The nephrotoxic effects of PZQ metabolite excretion through the kidney have not been assessed yet. This study investigated the relationship between number of Praziquantel treatments and kidney parenchymal change. A study was carried out on participants from the Cholangiocarcinoma Screening and Care Program (CASCAP) between 2013 - 2018. The frequency of PZQ use was reported using a standardized questionnaire. Kidney parenchymal change (KPC) was defined as having a kidney abnormality based on ultrasonography diagnosed by well-trained general practitioners. Adjusted odds ratios (ORs) measured associations between PZQ frequency and KPC controlling for the effects of other extraneous factors using multiple logistic regression. A total of 490,969 subjects with mean age of 55.2 (SD = 9.15) years were enrolled among them 62.1% were female. Prevalence of KPC was 1.2% while prevalence of KPC were 1.2%, 1.3%, 1.4%, and 1.5% for participants with one, two, three, and more than 3 PZQ treatment occasions respectively. Those dose-response relationship was statistically significant based on chi-square test for trend (p-value <0.001). After controlling for possible confounders, compared to non-treatment, subjects with more than 3 treatment occasions were 25% more likely to have a KPC positive result (OR = 1.25; 95% CI: 1.02 - 1.52; p-value = 0.028). The number of repeated PZQ treatments is statistically significantly related to KPC. This relationship could be included in health messaging for those who continue eating uncooked fish with an understanding that the OV infection can easily be cured by PZQ without any other health concerns. For positive OV cases, however, the known efficacy of PZQ could over-ride the small magnitude of the adverse effect.
Sections du résumé
BACKGROUND
BACKGROUND
In Northeast Thailand, Praziquantel (PZQ) is used to treat infection with the Opisthorchis viverrnini (OV). OV has highly prevalence in this area due to the traditional consumption of uncooked cyprinid fish. The nephrotoxic effects of PZQ metabolite excretion through the kidney have not been assessed yet. This study investigated the relationship between number of Praziquantel treatments and kidney parenchymal change.
METHODS
METHODS
A study was carried out on participants from the Cholangiocarcinoma Screening and Care Program (CASCAP) between 2013 - 2018. The frequency of PZQ use was reported using a standardized questionnaire. Kidney parenchymal change (KPC) was defined as having a kidney abnormality based on ultrasonography diagnosed by well-trained general practitioners. Adjusted odds ratios (ORs) measured associations between PZQ frequency and KPC controlling for the effects of other extraneous factors using multiple logistic regression.
RESULTS
RESULTS
A total of 490,969 subjects with mean age of 55.2 (SD = 9.15) years were enrolled among them 62.1% were female. Prevalence of KPC was 1.2% while prevalence of KPC were 1.2%, 1.3%, 1.4%, and 1.5% for participants with one, two, three, and more than 3 PZQ treatment occasions respectively. Those dose-response relationship was statistically significant based on chi-square test for trend (p-value <0.001). After controlling for possible confounders, compared to non-treatment, subjects with more than 3 treatment occasions were 25% more likely to have a KPC positive result (OR = 1.25; 95% CI: 1.02 - 1.52; p-value = 0.028).
CONCLUSION
CONCLUSIONS
The number of repeated PZQ treatments is statistically significantly related to KPC. This relationship could be included in health messaging for those who continue eating uncooked fish with an understanding that the OV infection can easily be cured by PZQ without any other health concerns. For positive OV cases, however, the known efficacy of PZQ could over-ride the small magnitude of the adverse effect.
Identifiants
pubmed: 35901347
doi: 10.31557/APJCP.2022.23.7.2397
pmc: PMC9727354
pii:
doi:
Substances chimiques
Anthelmintics
0
Praziquantel
6490C9U457
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2397-2405Références
J Egypt Public Health Assoc. 2019;94(1):8
pubmed: 30799879
J Am Soc Nephrol. 2002 Jan;13 Suppl 1:S37-40
pubmed: 11792760
Kidney360. 2020 Apr 24;1(7):671-675
pubmed: 35372930
Parasitol Int. 2012 Mar;61(1):10-6
pubmed: 21893213
Malawi Med J. 2017 Jun;29(2):166-170
pubmed: 28955427
Int J Urol. 1997 Nov;4(6):537-40
pubmed: 9477179
Int J Environ Res Public Health. 2020 Jun 09;17(11):
pubmed: 32526911
BMC Nephrol. 2017 Apr 3;18(1):115
pubmed: 28372539
Lancet. 2020 Feb 29;395(10225):709-733
pubmed: 32061315
Kidney Int. 2018 Sep;94(3):462-464
pubmed: 30078513
Liver Int. 2010 Feb;30(2):215-21
pubmed: 19840244
Infect Dis Poverty. 2019 Mar 20;8(1):18
pubmed: 30890188
AIDS. 2011 Aug 24;25(13):1603-9
pubmed: 21646902
BMC Nephrol. 2009 Oct 27;10:34
pubmed: 19860890
BMC Cancer. 2015 Oct 24;15:776
pubmed: 26496745
Acta Trop. 2003 Nov;88(3):229-32
pubmed: 14611877
BMC Nephrol. 2009 Oct 31;10:35
pubmed: 19878577
BMC Res Notes. 2014 Jul 02;7:415
pubmed: 24990184
Proc R Soc Med. 1965 May;58:295-300
pubmed: 14283879
Clin Kidney J. 2019 May 20;13(1):63-71
pubmed: 32082554
Nephron Clin Pract. 2011;119 Suppl 2:c239-48
pubmed: 21894036
Acta Trop. 2011 Sep;120 Suppl 1:S158-68
pubmed: 20655862
Korean J Parasitol. 2013 Dec;51(6):703-10
pubmed: 24516277
Appl Parasitol. 1994 Jun;35(2):118-24
pubmed: 8087151
Asian Pac J Cancer Prev. 2014;15(16):6609-12
pubmed: 25169496
BMC Public Health. 2009 Jan 31;9:44
pubmed: 19183493
Am J Kidney Dis. 2005 Jan;45(1 Suppl 1):A5-7, S1-280
pubmed: 15640975
Eur J Drug Metab Pharmacokinet. 1979;4(3):149-56
pubmed: 527600
BMC Genomics. 2007 Jun 22;8:189
pubmed: 17587442
PLoS Negl Trop Dis. 2010 Jun 22;4(6):e719
pubmed: 20582164
Asian Pac J Cancer Prev. 2016;17(2):857-62
pubmed: 26925692
Asian Pac J Cancer Prev. 2011;12(5):1367-70
pubmed: 21875298
BMC Cancer. 2015 Jun 09;15:459
pubmed: 26054405
Am J Kidney Dis. 2021 Apr;77(4 Suppl 1):A7-A8
pubmed: 33752804
Am J Trop Med Hyg. 1978 Jul;27(4):787-94
pubmed: 686245
Curr Opin Gastroenterol. 2008 May;24(3):349-56
pubmed: 18408464
Kidney Int. 2012 Aug;82(3):270-7
pubmed: 22437416
J Antimicrob Chemother. 2014 Apr;69(4):863-70
pubmed: 24390933
Kidney Int. 2008 Feb;73(4):473-9
pubmed: 18059458
BMC Public Health. 2020 Aug 27;20(1):1299
pubmed: 32854662
Kidney Int. 2007 Dec;72(11):1380-7
pubmed: 17805235